The 2009 H1N1 influenza pandemic demonstrated the significance of a global health threat to human beings. Although pandemic H1N1 vaccines have been rapidly developed, passive serotherapy may offer superior immediate protection against infections in children, the elderly and immune-compromised patients during an influenza pandemic. Here, we applied a novel strategy based on Epstein-Barr virus (EBV)-immortalized peripheral blood memory B cells to screen high viral neutralizing monoclonal antibodies (MAbs) from individuals vaccinated with the 2009 pandemic H1N1 vaccine PANFLU.1. Through a massive screen of 13 090 immortalized memory B-cell clones from three selected vaccinees, seven MAbs were identified with both high viral neutralizing capacities and hemagglutination inhibition (HAI) activities against the 2009 pandemic H1N1 viruses. These MAbs may have important clinical implications for passive serotherapy treatments of infected patients with severe respiratory syndrome, especially children, the elderly and immunodeficient individuals. Our successful strategy for generating high-affinity MAbs from EBV-immortalized peripheral blood memory B cells may also be applicable to other infectious or autoimmune diseases.
INTRODUCTION
The 2009 pandemic H1N1 influenza pandemic raised major public concern worldwide. It was reported that the outbreak of 2009 H1N1 pandemic strain caused more than 60 million cases, more than 256 000 of which required hospitalization. [1] [2] [3] Although the 2009 H1N1 pandemic influenza virus did not cause high mortality, an unusually high frequency of severe syndromes occurred in young children and the elderly. 4 Fortunately, an efficient H1N1 vaccine, PANFLU.1, became available five months after the outbreak of 2009 influenza pandemic. One dose of non-adjuvant split-virion vaccine, containing 7.5 mg hemagglutinin (HA), induced seroprotection in more than 90% of people between the ages 12 and 60 years. 5 However, only 76.7% of children aged from 3 to 12 years and 80.3% in people over 60 years were seroprotected by this vaccine. 5 Importantly, children and the elderly were particularly vulnerable to pandemic H1N1 influenza infection and suffered significantly higher mortality during the outbreak in 2009. 1 Despite the rapid development of pandemic H1N1 vaccines and the fast-tracked approval processes, these products were not available for large-scale use until the end of the 2009 pandemic. Therefore, during an outbreak of pandemic influenza, it is critical to develop passive serotherapy to provide immediate protection against infections for young children, the elderly and medical personnel. Passive serotherapy can also be used as a cure for infected individuals with deadly respiratory syndrome, especially for immunocompromised patients.
During the outbreak of pandemic influenza A in 2009, insufficient amounts of human sera containing antibodies to pandemic influenza A H1N1 virus were available for the large population of infected patients. Therefore, we considered the generation of human monoclonal antibodies (MAbs) with high viral neutralizing capacities to influenza A H1N1 virus as an effective solution. A number of strategies have been reported to generate human MAbs, such as (i) hybridoma generation via fusing human B cells with a myeloma cell line; 6, 7 (ii) immortalizing B cells with Epstein-Barr virus (EBV); 8, 9 (iii) humanizing murine MAbs; 10, 11 (iv) selection of positive antibody fragments from phage-display libraries; 12, 13 (v) production of human MAbs from vaccinated transgenic mice carrying human immunoglobulin loci; 14 and (vi) expression of human MAbs by protein engineering with the variable genes of MAbs from antibody-secreting plasma cells of infectious patients. 4, 15 The success of the 2009 H1N1 vaccine PANFLU.1 in young adults provided a possibility for screening high viral neutralizing MAbs from vaccinated individuals. Accordingly, in the present study, we applied a novel strategy based on EBVimmortalized peripheral blood memory B cells to screen 2009 pandemic H1N1 influenza strain-specific neutralizing MAbs from vaccinated individuals who received PANFLU.1. Through a massive screen of 13 090 immortalized B-cell clones from three selected vaccinees with hyperimmune sera, seven clones were identified to produce MAbs with both high viral neutralizing capacities and hemagglutination inhibition (HAI) activities. These EBV-immortalized memory B-cell clones can generate high viral neutralizing MAbs for clinical passive serotherapy of infected patients with severe respiratory syndrome, especially children, the elderly and immunodeficient individuals. This novel EBV-immortalized memory B-cell strategy may also be applicable to other infectious or autoimmune diseases.
MATERIALS AND METHODS

Cell cultures
The marmoset B-lymphoblastoid cell line B95-8 and 293T cells were cultured in RPMI 1640 medium containing L-glutamine (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (FCS) and penicillin-streptomycin at 37 uC in a humidified incubator with 5% CO 2 . MDCK cells were cultured in DMEM medium (Invitrogen) supplemented with 10% FCS. Spodoptera frugiperda (Sf9) cells were maintained in Sf-900 II SFM (Invitrogen).
Volunteers enrolled in the experiments
Fourteen young healthy young adults were vaccinated with 2009 H1N1 pandemic vaccine PANFLU.1 (Sinivac Biotech China) at the Institute of Basic Medical Science, Peking Union Medical College. Five healthy unvaccinated volunteers were used as negative controls.
Isolation of memory B cells
Peripheral blood memory B cells were isolated using a magnetic isolation kit (Miltenyi, Bergisch Gladbach, Germany) as described previously. 16 In brief, peripheral blood mononuclear cells (PBMCs) were isolated from the vaccinees and unvaccinated healthy controls. Non-memory B cells in PBMCs, including T cells, natural killer cells, monocytes, dendritic cells, granulocytes, platelets and erythroid cells, were depleted using a cocktail of biotinylated antibodies against CD2, CD14, CD16, CD36, CD43 and CD235a (glycophorin A), and anti-biotin microbeads. Subsequently, magnetic labeling of memory B cells with CD27 microbeads were performed for positive selection of memory B cells.
Flow cytometry
Isolated cells ware analyzed by a standard flow cytometry protocol as described previously. 17 Briefly, cells were washed with phosphate-buffered saline containing 1% bovine serum albumin and incubated with surface-staining antibodies. After staining with FITC-conjugated CD27, PE-conjugated CD19 (Miltenyi Biotech) at 4 uC for 20 min, cells were washed with phosphate-buffered saline and resuspended in 300 ml phosphatebuffered saline. The data were analyzed using FlowJo software (Version 5.7.2; Tree Star, Inc., Ashland, OR, USA).
EBV preparation and immortalization of peripheral blood memory B cells EBV for immortalization of human B lymphocytes was prepared from B95-8 cells, as described previously. 18 In short, B95-8 cells were cultured at a high density of 10 6 cells/ml in RPMI 1640 with 10% (v/v) FCS at 37 uC in 5% CO 2. The supernatant was collected and filtered with a sterile filter (0.45 mm; Millipore, Billerica, MA, USA) before storing the aliquots in liquid nitrogen. Peripheral blood memory B cells were EBV-transformed according to the protocol, as described previously. 19 Allogenic mononuclear cells (5310 5 cells/ml) in RPMI 1640 medium without sera were irradiated by 35 Grey Co 60 and plated in 96-well plates (50 000 cells/ 100 ml per well) in 30% FCS. These irradiated cells were used as feeding cells. Using flow cytometry, memory B cells were sorted into a single cell per well into 96-well plates with feeding cells before the addition of 50 ml mixture per well containing 48 ml of EBV suspension, 1 ml of cyclosporine A solution (at the final concentration of 400 ng/ml) and 1 ml of CpG 2006 (at final concentration of 2.5 mg/ml). After EBV transformation, immortalized memory B-cell clones were expanded for 28 days with medium changed every 3-5 days. The supernatant of each clone (100 ml) was used to screen positive clones specific for 2009 pandemic (H1N1) HA.
Expression of recombinant HA proteins (rHAs) rHAs were expressed and purified using the Baculovirus/insect cell system (BD Biosciences, San Diego, CA, USA), as described previously. 20, 21 In brief, the HA ectodomain DNA fragment of A/ Sichuan/1/2009 (H1N1) HA gene was cloned into the transfer vector PacGP67b (BD Biosciences). Linearized baculovirus DNA (BD Biosciences) and the transfer vector PacGP67b were cotransfected into Sf9 cells for the generation of recombinant baculoviruses. Viral supernatant was collected at 72 h post-infection. rHAs were expressed after three rounds of infection and purified using Ni-NTA chromatography (GE Healthcare, Pittsburgh, PA, USA). Western blotting confirmed the expression and purification of rHAs with anti-His or anti-HA antibodies.
Production of pseudotype influenza virus
Pseudotype H1N1 viruses were generated as described previously. 20, 22 Briefly, pseudotype influenza viruses were produced 
Enzyme-linked immunosorbent assay (ELISA)
ELISAs were performed to measure the HA-binding activities of sera from vaccinees or MAbs from immortalized memory B cells, as described previously. 20 Briefly, rHAs were coated on polystyrene plates at 4 uC overnight followed by blocking with 5% bovine serum albumin (Sigma, St Louis, MO, USA) at 37 uC for 1 h. The sera from vaccinees at a dilution of 1 : 100 were incubated in wells at 37 uC for 1 h. After complete wash, horseradish peroxidase-labeled anti-human IgG or IgM (1 : 5000) (Sigma) was added at 37 uC for 1 h. The OPD/H 2 O 2 was added to develop color, and the reaction was stopped with 50 ml of H 2 SO 4 . Plates were detected at 450/630 nm.
Western blot rHAs were resolved using SDS-polyacrylamide gel electrophoresis and electrophoretically transferred to a nitrocellulose membrane. After blocking with 5% skim milk, the blots were probed with anti-His-tag mouse MAbs at room temperature for 1 h. After a complete wash, horseradish peroxidaseconjugated anti-mouse IgG was added and incubated at room temperature for 1 h before protein detection with the West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA).
HAI assay HAI assays of sera or MAbs were performed according to a standard hemagglutination-inhibition protocol. 20, 23, 24 Briefly, sera from vaccinees or MAbs from immortalized memory B cells were diluted initially at 1 : 5 and treated overnight with Vibrio cholerae receptor-destroying enzyme (Denka-Seiken, Tokyo, Japan) followed by inactivation for 30 min at 56 uC to destroy non-specific inhibitors. Serial dilutions of sera or MAbs were pre-incubated with pseudotype H1N1 virus (4 HA units per well) for 30 min incubation. To wells, 0.75% type-O human erythrocytes were added, and the plates were incubated on ice for 30 minutes. Positive seroprotection was set at a geometric mean titer over 1 : 40.
Neutralization assays Neutralization assays of sera or MAbs were performed as described previously. 21, 24 Serial dilutions of sera or MAbs were incubated with pseudotype H1N1 viruses for 30 min at room temperature before the mixture was added to MDCK cells in 96-well plates. Infection efficiency was quantified by measuring the luciferase activity in the target cells with an EG&G Berthold Microplate Luminometer LB96V. The neutralization activity of sera or MAbs was analyzed according to the equation: (A-B)/ A3100%. 'A' represents the value of positive wells that contained only pseudotype viruses, and 'B' represents the value of wells that contained the mixture of testing serum samples and pseudotype viruses.
Statistical analysis
Data are presented as the mean6s.d. of triplicate experiments. Unpaired Student's t-test was used for statistical evaluation of the differences among the diverse human MAbs or human sera in HA-binding assays, HAI or neutralizing assays. P values of less than 0.05 were considered statistically significant.
RESULTS
Vaccination of volunteers with 2009 H1N1 vaccine PANFLU.1
To generate high viral neutralizing MAbs against 2009 pandemic H1N1 strains, we applied a novel strategy using EBV to immortalize peripheral blood memory B cells from vaccinees who received the 2009 H1N1 vaccine PANFLU.1 ( Figure 1 ). Because PANFLU.1 appeared to be more effective against H1N1 virus infection in young adults, 25, 26 we selected 19 healthy volunteers between 24 and 45 years of age for screening vaccinees with high viral neutralizing sera. Fourteen volunteers were vaccinated with one dose of PANFLU.1 containing 15 mg of HA antigen, and five healthy unvaccinated volunteers were used as a negative control. 
Expression of recombinant HA proteins derived from 2009 pandemic H1N1 virus
Previous studies demonstrated that a majority of neutralizing antibodies against pandemic H1N1 viruses were able to bind to highly conserved epitopes in the stalk and head regions of HA proteins. 4, 27 Antibodies against the surface glycoprotein HA are of major importance for protection against infection. Thus, HA is the primary component of currently licensed influenza virus vaccines. 2 In this study, we used rHAs to screen neutralizing antibodies specific for the 2009 pandemic H1N1 virus. The ectodomain of HA from 2009 pandemic H1N1 virus was fused with a His tag at the C-terminus expressed in baculovirus-infected Sf9 insect cells and purified by metal affinity chromatography. Coomassie blue staining confirmed that the size of rHAs was correct and the purity was greater than 80% (Figure 2a) . Western blotting also confirmed that rHAs were successfully expressed and purified (Figure 2b) . A HA assay showed that the rHAs possessed HA comparable activities with the 2009 H1N1 pandemic vaccine (Figure 2c and d) . These results suggest that the rHAs could be used to screen high affinity HA-specific antibodies specific for the 2009 pandemic H1N1 virus.
Selection of vaccinees with hyperimmune sera
To verify the vaccination efficiency of PANFLU.1, the sera from 14 vaccinees were analyzed using an ELISA to assess HA-binding and using a neutralizing capacity assay at different time points after vaccination (Figure 3a) . The sera from the vaccinated group had significantly higher HA-binding activity and stronger neutralizing capacity for the 2009 pandemic pseudotype H1N1 virus compared with unvaccinated healthy controls (P,0.01, ANOVA) (Figure 3a and b) . The HA-binding activities and neutralizing capacities for the 2009 pandemic pseudotype H1N1 virus remained at relatively high levels between 2 and 8 weeks after vaccination (Figure 3a and b) . This finding is consistent with previous studies. 9, 19 At 8 weeks postvaccination, sera from all 14 vaccinees had high binding to rHA and neutralizing capacities for the 2009 pandemic pseudotype H1N1 virus (Figure 3c and d) . In contrast, all five unvaccinated healthy controls had no antibody response to either rHA or the 2009 pandemic pseudotype H1N1 virus. Notably, vaccinee 4 (V4) had approximately twofold higher HA-binding activities compared with other vaccinees (Figure 3c) . A HAI assay showed that sera from all 14 vaccinees were HAI-positive (HAI 1 ) (defined as positive at a minimum sera dilution .1 : 40), while sera from the five unvaccinated healthy volunteers were HAI-negative (HAI 2 ) (Figure 3e 
CD27
1 memory B cells were individually sorted into 96-well plates (single cell per well) containing EBV, CpG2006 and feeding cells. 
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Screening immortalized memory B-cell clones secreting HAspecific MAbs To identify HA-specific antibody-producing immortalized memory B-cell clones, 13 090 immortalized memory B-cell clones were screened by using ELISA to measure the HAbinding activities. Of these, 617 clones were identified as positive clones (Figure 5a-c) , 281 of which were derived from V4 (Figure 5a ). The mean frequency of HA-specific antibody-producing memory B-cell clones was 4.82% (Figure 5d ). An HAI assay was performed to test the hemagglutination inhibition activities of 617 clones, and 32 clones, including 16 clones derived from V4, were HAI 1 (Figure 5e ). Compared to other techniques for generating human MAbs, such as humanizing murine MAbs or selection of antibody fragments from phage-display libraries, 10-13 our strategy has two major advantages. First, the seven immortalized memory B-cell clones were 2009 pandemic H1N1 influenza strainspecific memory B cells proliferating in response to the specific vaccine, and they were not resting memory B cells, which are composed of a range of B-cell clones generated by a variety of previous exposures. Second, compared to generating immortalized B-cell clones from influenza-infected patients, it appears to be more efficient to obtain high neutralizing activity MAbs against pandemic influenza H1N1 viruses from selected healthy vaccinees. Serum from V4 had significantly higher titers of neutralizing activity and HA-binding activity than those from any other vaccinees. In fact, six of nine immortalized memory B-cell clones were derived from V4. These results indicate that the antibody response to pandemic H1N1 2009 vaccine may be variable among vaccinated individuals, though we could not exclude the possibility of pre-existence of anti-HA antibodies in V4 due to previous H1N1 viral infection. Therefore, it was necessary to screen the vaccinees with hyperimmune sera before the generation of human MAbs from immortalized memory B-cell clones.
Identification of high viral neutralizing MAbs
Recently, several studies reported success in generating neutralizing antibodies from peripheral blood plasma cells of vaccinated individuals or infected patients. 4, 15, 28, 29 However, because peripheral blood plasma cells could only survive 1-2 weeks after vaccination or infection, they identified the genes encoding human variable regions using single-cell RT-PCR of plasmablasts and subsequently expressed the antibodies in Escherichia coli. 15 Clearly, the MAbs from immortalized human memory B-cell clones are more natural and stable in viral neutralizing activities over a lifetime and are more suitable for clinical applications.
In this study, we found that, although nine identified MAbs displayed high viral neutralizing activities, two of them were negative in the HAI assay, indicating that the epitopes recognized by these two MAbs may be located at the stem region of HA proteins, consistent with previous descriptions. 4, 15, 28, [30] [31] [32] [33] [34] [35] Escape mutation, overlapping the HA peptide-binding assay and competition ELISA may be useful for identifying their epitopes in future studies. We also found that 4.82% of MAbs isolated from immortalized memory B cells had HAbinding activity, but only 0.24% had HAI activity and only 0.061% of MAbs could efficiently neutralize H1N1 viruses. These data indicate that the frequency of memory B cells specifically reactive against 2009 pandemic H1N1 viruses is low but detectable in the whole memory B-cell repertoire, consistent with the studies reported previously. 9, 15 Passive serotherapy with polyclonal or MAbs has been widely used for infectious diseases such as respiratory syncytial virus, Hepatitis A and B, anthrax, smallpox, meningitis and the plague. 10, [36] [37] [38] [39] In the case of influenza, serotherapy with MAbs has also provided prophylactic or therapeutic protection in mice and other animal models. 4, 40, 41 In this study, we developed seven MAbs with high neutralizing capacities against 2009 pandemic H1N1 viruses. Our findings suggest that these MAbs may provide potent therapeutics for treating severe influenza cases and protecting high-risk populations such as children, the elderly and immunodeficient individuals.
In addition, compared with conventional methods, the strategy used in this study is a rapid method for generating human neutralizing MAbs from peripheral blood memory B cells with high efficiency and accuracy. This method bypasses the need for generating humanized hybridomas and can deliver large numbers of antibodies, making it easier to select the most favorable antibodies with high affinity or titer and epitope specificity. Moreover, this strategy would also be applicable for rapid generation of neutralizing antibodies in a pandemic outbreak of other emerging pathogens and contributes to the serotherapy field for infectious or autoimmune diseases.
